CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Cellectis (CLLS) remained on investors’ radar on Tuesday as the biotech firm received a downgrade from Citizens after it stopped further development of its lead blood-cancer treatments and shifted its focus toward cardiovascular diseases.Citizens downgraded Cellectis to ‘Market Perform’ from ‘Outpe…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.